BRIM Biotechnology, Inc. products

Novel drugs to relieve and repair tissue damage caused by osteoarthritis. BRIM Biotechnology is developing novel drugs to relieve and repair tissue damage caused by osteoarthritis. BRM521’s unique mechanism of action promotes joint cartilage regeneration and relieves pain.

BRM423 is targeted to treat severe corneal damage. BRM423 is novel synthetic peptide derived from human Pigment Epithelium-Derived Factor (PEDF). Its active ingredient is the same as the BRM421 for Dry Eye Syndrome, but it is targeted to treat severe corneal damage. Based on BRIM’s proprietary PDSP technology platform, BRIM intends to rapidly advance development of this novel treatment for corneal damage repair.

Neurotrophic Keratitis is a rare, degenerative disease characterised by corneal sensitivity reduction, spontaneous epithelium breakdown, and impairment of corneal healing. Currently, there is only one drug, Oxervate (Cenegermin), approved by the US FDA and EMA in 2018. Eye health is crucial to quality of life and BRIM is advancing new therapeutics to support patients affected by Neurotrophic Keratitis.

Our lead asset, BRM421, is on track to become a first-in-class treatment for Dry Eye Syndrome (DES) which treats and repairs corneal damage. BRIM Biotechnology is accelerating the cycle of innovation by leveraging its PDSP technology platform to bring novel ophthalmology treatments to market.